Display options
Cite
Chen J, Patel R, Friedman TC, et al. The Behavioral and Pharmacological Actions of NMDA Receptor Antagonism are Conserved in Zebrafish Larvae. Int J Comp Psychol. 2010;23(1):82-90
Chen, J., Patel, R., Friedman, T. C., & Jones, K. S. (2010). The Behavioral and Pharmacological Actions of NMDA Receptor Antagonism are Conserved in Zebrafish Larvae. International journal of comparative psychology, 23(1), 82-90.
Chen, John, et al. "The Behavioral and Pharmacological Actions of NMDA Receptor Antagonism are Conserved in Zebrafish Larvae." International journal of comparative psychology vol. 23,1 (2010): 82-90.
Chen J, Patel R, Friedman TC, Jones KS. The Behavioral and Pharmacological Actions of NMDA Receptor Antagonism are Conserved in Zebrafish Larvae. Int J Comp Psychol. 2010;23(1):82-90. PMID: 21278812; PMCID: PMC3027073.
Copy Download .nbib Format: NLM
Share it on

Int J Comp Psychol. 2010;23(1):82-90.

The Behavioral and Pharmacological Actions of NMDA Receptor Antagonism are Conserved in Zebrafish Larvae.

International journal of comparative psychology

John Chen, Roshni Patel, Theodore C Friedman, Kevin S Jones

PMID: 21278812 PMCID: PMC3027073

Abstract

Dizocilpine maleate (MK-801) is one of several NMDA receptor antagonists that is widely used to pharmacologically model the symptoms of psychosis and schizophrenia in animals. MK-801 elicits behaviors in adult zebrafish (Danio rerio) that are phenotypically consistent with behaviors observed in humans and rodents exposed to tbhe drug. However, the molecular and cellular processes that mediate the psychotomimetic, cognitive and locomotive behaviors of MK-801 are unclear. We exposed zebrafish larvae to MK-801 to assess their merit as a model organism to elucidate the behavioral effects of NMDA receptor blockade. Zebrafish larvae were acutely immersed in MK-801 to assess the effect on spontaneous swimming. MK-801 caused a time- and dose-dependent increase in larval swim speed, and the peak response (a five-fold increase in swim speed) was evoked by a three h exposure to a 20 uM dose. Zebrafish larvae did not exhibit sensitivity to the locomotor effects of MK-801 until 5 dpf, suggesting a critical role for developmental in sensitivity to the drug. Exposure to the low potency NMDA antagonist, memantine, did not alter the swim speed of zebrafish larvae. Co-immersion in D(1) or D(2) dopamine receptor antagonists did not disrupt the time course or magnitude of the increase in swim speed, suggesting dopaminergic signaling is not required for the locomotor actions of MK-801. Our findings of the behavioral actions of MK-801 in zebrafish larvae are consistent with previous observations in mammals and imply that the physiological, cellular and molecular processes disrupted by MK-801 are conserved in zebrafish larvae. These data suggest that the zebrafish larvae is a valid and useful model to elucidate neurobehavioral aspects of NMDA receptor antagonism and may provide insight to the neurobiology of psychosis and schizophrenia.

References

  1. Eur J Pharmacol. 1992 May 14;215(2-3):199-208 - PubMed
  2. Psychopharmacology (Berl). 2009 Aug;205(2):203-16 - PubMed
  3. Comp Biochem Physiol A Mol Integr Physiol. 2006 Mar;143(3):332-9 - PubMed
  4. J Neurosci. 1998 Nov 15;18(22):9181-91 - PubMed
  5. Dev Dyn. 1995 Jul;203(3):253-310 - PubMed
  6. AMA Arch Neurol Psychiatry. 1959 Mar;81(3):363-9 - PubMed
  7. Neuropsychopharmacology. 1999 Mar;20(3):201-25 - PubMed
  8. Neurosci Biobehav Rev. 2002 Jun;26(4):441-55 - PubMed
  9. Neuropharmacology. 1996 Apr;35(4):467-74 - PubMed
  10. Mol Psychiatry. 2004 Nov;9(11):984-97, 979 - PubMed
  11. Pharmacol Biochem Behav. 1991 Oct;40(2):291-5 - PubMed
  12. Arch Gen Psychiatry. 1994 Mar;51(3):199-214 - PubMed
  13. Proc Natl Acad Sci U S A. 1986 Sep;83(18):7104-8 - PubMed
  14. Dev Psychobiol. 1974 Jan;7(1):47-60 - PubMed
  15. Psychopharmacology (Berl). 1981;73(2):103-9 - PubMed
  16. Pharmacol Rev. 1999 Mar;51(1):7-61 - PubMed
  17. J Exp Biol. 2000 Sep;203(Pt 17):2565-79 - PubMed
  18. Am J Psychiatry. 1973 Oct;130(10):1088-93 - PubMed
  19. Neuropsychopharmacology. 2005 Jul;30(7):1324-33 - PubMed
  20. Pharmacopsychiatry. 1998 Jul;31 Suppl 2:73-9 - PubMed
  21. Ann N Y Acad Sci. 2003 Nov;1003:318-27 - PubMed
  22. Psychopharmacology (Berl). 1995 Feb;117(3):313-7 - PubMed
  23. Am J Psychiatry. 1991 Oct;148(10):1301-8 - PubMed
  24. Neurotoxicol Teratol. 2004 Nov-Dec;26(6):725-9 - PubMed
  25. Semin Cancer Biol. 2007 Apr;17(2):154-65 - PubMed
  26. Dev Dyn. 2005 Nov;234(3):756-66 - PubMed
  27. J Neural Transm. 1986;67(3-4):225-40 - PubMed
  28. J Neurosci. 2007 May 2;27(18):4984-94 - PubMed
  29. J Exp Biol. 2007 Jul;210(Pt 14):2526-39 - PubMed

Publication Types

Grant support